These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19798725)

  • 1. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.
    Mendell JR; Rodino-Klapac LR; Rosales-Quintero X; Kota J; Coley BD; Galloway G; Craenen JM; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Viollet L; Walker CM; Sahenk Z; Clark KR
    Ann Neurol; 2009 Sep; 66(3):290-7. PubMed ID: 19798725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.
    Mendell JR; Rodino-Klapac LR; Rosales XQ; Coley BD; Galloway G; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Taylor LE; Flanigan KM; Gastier-Foster JM; Astbury C; Kota J; Sahenk Z; Walker CM; Clark KR
    Ann Neurol; 2010 Nov; 68(5):629-38. PubMed ID: 21031578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
    Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
    Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy.
    Griffin DA; Pozsgai ER; Heller KN; Potter RA; Peterson EL; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):390-404. PubMed ID: 33349138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.
    Herson S; Hentati F; Rigolet A; Behin A; Romero NB; Leturcq F; Laforêt P; Maisonobe T; Amouri R; Haddad H; Audit M; Montus M; Masurier C; Gjata B; Georger C; Cheraï M; Carlier P; Hogrel JY; Herson A; Allenbach Y; Lemoine FM; Klatzmann D; Sweeney HL; Mulligan RC; Eymard B; Caizergues D; Voït T; Benveniste O
    Brain; 2012 Feb; 135(Pt 2):483-92. PubMed ID: 22240777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice.
    Nishiyama A; Ampong BN; Ohshima S; Shin JH; Nakai H; Imamura M; Miyagoe-Suzuki Y; Okada T; Takeda S
    Hum Gene Ther; 2008 Jul; 19(7):719-30. PubMed ID: 18578595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion.
    Mendell JR; Chicoine LG; Al-Zaidy SA; Sahenk Z; Lehman K; Lowes L; Miller N; Alfano L; Galliers B; Lewis S; Murrey D; Peterson E; Griffin DA; Church K; Cheatham S; Cheatham J; Hogan MJ; Rodino-Klapac LR
    Hum Gene Ther; 2019 Jul; 30(7):794-801. PubMed ID: 30838895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?
    Klinge L; Dekomien G; Aboumousa A; Charlton R; Epplen JT; Barresi R; Bushby K; Straub V
    Neuromuscul Disord; 2008 Dec; 18(12):934-41. PubMed ID: 18996010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epsilon-sarcoglycan compensates for lack of alpha-sarcoglycan in a mouse model of limb-girdle muscular dystrophy.
    Imamura M; Mochizuki Y; Engvall E; Takeda S
    Hum Mol Genet; 2005 Mar; 14(6):775-83. PubMed ID: 15689353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice.
    Pozsgai ER; Griffin DA; Heller KN; Mendell JR; Rodino-Klapac LR
    Gene Ther; 2016 Jan; 23(1):57-66. PubMed ID: 26214262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel SGCA missense mutation in a case of limb-girdle muscular dystrophy 2D with the absence of four sarcoglycan proteins.
    Lu Y; Song X; Ji G; Wu H; Li D; Sun S
    Neuropathology; 2019 Jun; 39(3):207-211. PubMed ID: 30989758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D.
    Pacak CA; Walter GA; Gaidosh G; Bryant N; Lewis MA; Germain S; Mah CS; Campbell KP; Byrne BJ
    Mol Ther; 2007 Oct; 15(10):1775-81. PubMed ID: 17653106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice.
    Xu R; DeVries S; Camboni M; Martin PT
    Am J Pathol; 2009 Jul; 175(1):235-47. PubMed ID: 19498002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repairing folding-defective α-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D.
    Carotti M; Marsolier J; Soardi M; Bianchini E; Gomiero C; Fecchio C; Henriques SF; Betto R; Sacchetto R; Richard I; Sandonà D
    Hum Mol Genet; 2018 Mar; 27(6):969-984. PubMed ID: 29351619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping.
    Gao QQ; Wyatt E; Goldstein JA; LoPresti P; Castillo LM; Gazda A; Petrossian N; Earley JU; Hadhazy M; Barefield DY; Demonbreun AR; Bönnemann C; Wolf M; McNally EM
    J Clin Invest; 2015 Nov; 125(11):4186-95. PubMed ID: 26457733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The first case of primary alpha-sarcoglycanopathy identified in Albania, in two siblings with homozygous alpha-sarcoglycan mutation.
    Babameto-Laku A; Tabaku M; Tashko V; Cikuli M; Mokini V
    Genet Couns; 2011; 22(4):377-83. PubMed ID: 22303798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector.
    Fougerousse F; Bartoli M; Poupiot J; Arandel L; Durand M; Guerchet N; Gicquel E; Danos O; Richard I
    Mol Ther; 2007 Jan; 15(1):53-61. PubMed ID: 17164775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sarcoglycans, vinculin-talin-integrin system and filamin2 in alpha- and gamma-sarcoglycanopathy: an immunohistochemical study.
    Anastasi G; Cutroneo G; Trimarchi F; Santoro G; Bruschetta D; Bramanti P; Pisani A; Favaloro A
    Int J Mol Med; 2004 Dec; 14(6):989-99. PubMed ID: 15547664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcolemmal alpha and gamma sarcoglycan protein deficiencies in Turkish siblings with a novel missense mutation in the alpha sarcoglycan gene.
    Diniz G; Tosun Yildirim H; Akinci G; Hazan F; Ozturk A; Yararbas K; Tukun A
    Pediatr Neurol; 2014 Jun; 50(6):640-7. PubMed ID: 24742800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new evidence for the maintenance of the sarcoglycan complex in muscle sarcolemma in spite of the primary absence of delta-SG protein.
    Gouveia TL; Kossugue PM; Paim JF; Zatz M; Anderson LV; Nigro V; Vainzof M
    J Mol Med (Berl); 2007 Apr; 85(4):415-20. PubMed ID: 17265058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.